Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
Reflection AI Eyes $25 Billion Valuation in Massive $2.5 Billion Funding Round 
Lynas Rare Earths Signs Vietnam Deal with LS Eco Energy to Boost Magnet Metal Production 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Oil Prices Rebound as Iran Denies U.S. Talks Amid Gulf War Supply Fears 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Australia's Inflation Eases in February but Core Pressures Persist 
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling 
CK Hutchison's Panama Ports Dispute Escalates as Arbitration Claims Surpass $2 Billion 
Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Samsung Biologics contradicted reports that it will be producing Pfizer’s coronavirus vaccine. There were news going around saying the South Korean biotechnology company headquartered in Incheon is set to start the production of the said American pharmaceutical corp’s COVID-19 vaccine soon.
False manufacturing deal report?
As per The Korea Herald, Samsung Biologics said that the report that was published by the Korea Economic Daily was “not factual.” In the report, it was claimed that the Korean firm is in talks with Pfizer for a manufacturing deal.
An unnamed source from the government allegedly said, “If all goes well, the company will be able to begin mass production of the vaccine in August at the earliest.”
However, Samsung Biologics is saying there is no such deal and not even a discussion about any contract to produce the vaccines for Pfizer. Besides, the American pharma company does not appear to have a problem in producing huge amounts of vaccine doses by itself.
In fact, Bloomberg reported just last week that Pfizer and BioNTech can produce as many as 3 billion doses of their coronavirus vaccine in this year alone. This is said to be more than double the number that the company’s partners had predicted six months ago.
What’s more, Pfizer and BioNTech are reportedly further increasing their production capacity for next year. They are aiming to manufacture more than 3 billion vials of the vaccine. The boost in production comes as the demand has also surged around the world.
Pfizer also deny production outside of its manufacturing lines
It was reported that Pfizer is exclusively manufacturing its own vaccine in its two dedicated supply lines located in Europe and the U.S. The doses made here are for global distribution.
“At this time, we are not in discussions for any additional manufacturing outside these established supply lines for this vaccine,” Pfizer said. “Once the pandemic supply phase is over and we enter a phase of regular supplies, Pfizer will certainly evaluate all additional opportunities available.”
Meanwhile, South Korea is one of the countries that are waiting for deliveries of Pfizer vaccines. It was said that the Korean government has a contract with the vaccine maker for the supply of 66 million doses of its COVID-19 vaccine.
